Thanks
I know a few years back ENZC mentioned that their solution to HIV will be a "faction" of the cost to what is currently available.
The info below is from a PR dated March 14, 2022:
While the healthcare focus for the last 2 years has been on the COVID-19
pandemic, the HIV pandemic has continued unabated. Over 16 million people are
infected with HIV, with approximately 10% being children. There are 1.7
Million new cases each year and approximately 1 Million deaths. Over 50% of
the worldwide patients with HIV/AIDS are located in Africa.
The only therapy for treating infected patients is antirational (ARV) drugs,
but these drugs are not available to 27% of those infected. The ARV therapies
which are available cause substantial side effects and are expensive. The ARV
therapy Biktarvy produced by Gilead costs $42,635 per year. The global HIV
market is estimated to be over $30 billion this year and is expected to grow
to over $36 billion globally by 2027.
The info below is from a PR dated April 25, 2022:
The statistics for HIV are alarming.
* Of the 34 Million individuals living with the HIV virus today, only 66%
had access to antiretroviral treatment - leaving 34% with no treatment.
* 1.7 million people become newly infected with HIV each year.
* 1 Million people die yearly from AIDS-related illnesses. 2,700 die each
day - over 300 are children (almost twice the number who die from cancer).
* 32.7 million people have died from AIDS-related illnesses since the start
of the pandemic.
Antiretroviral drugs have significant drawbacks.
* They do not cure a patient and must be taken for life.
* They are extremely expensive.
* The cost of Biktarvy by Gilead is $42,635 per year.
* The cost of Dovato by ViiV Healthcare/GSK is $27,540 per year.
* The cost of Dolutegravir/tenofovir is $48,000 per year.
* It is well recognized (even by the producers of these drugs - as is
publicly revealed in advertisements for the drugs) that these
antiretroviral drugs cause serious damage over time to the heart and
the kidneys, they decrease bone density, and they contribute to
Vitamin D deficiency. These are only some of the potential negative
side effects attributed to the therapies.
* HIV infections are most treatable during their earlier stages, and
patients cannot take antiretrovirals during earlier stages since drug
resistance often develops.
* Limited or no treatment options exist when viral load and CD4 cell counts
are at their worst, i.e., AIDS.
The reason these ARV drugs do not cure is because they do not act on the virus
in the same way that our ITV-1 therapeutics or our a monoclonal antibody can.
In the case of using monoclonal antibodies, our technology is to produce
monoclonal antibodies that target immutable, conserved epitopes on the virus
so that a therapeutic cure may be achieved.
